<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948801</url>
  </required_header>
  <id_info>
    <org_study_id>[2018]02-417-01</org_study_id>
    <nct_id>NCT04948801</nct_id>
  </id_info>
  <brief_title>SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients</brief_title>
  <official_title>SOF/VEL±RBV: Real-World Efficacy and Safety in GT 3 and 6 HCV Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      150 GT3 or GT6 CHC patients with or without compensated cirrhosis will be recruited from five&#xD;
      centers in China including G3a 50, G3b 50, G6 50 respectively. GT3a and GT6 CHC with or&#xD;
      without compensated patients will be administered one pill of Epclusa each day for 12 weeks,&#xD;
      and GT3b patients will be administered Epclusa each plus Ribavirin for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Prospective, observational, multi-center, real-world study to investigate real&#xD;
      world effectiveness and safety of SOF/VEL±RBV in Chinese patients infected by HCV GT-3 and 6.&#xD;
      150 GT3 or GT6 CHC patients with or without compensated cirrhosis will be recruited from five&#xD;
      centers in China including G3a 50, G3b 50, G6 50 respectively. GT3a and GT6 CHC with or&#xD;
      without compensated cirrhosis will be administered one pill of Epclusa each day for 12 weeks,&#xD;
      and GT3b patients will be administered one pill of Epclusa each plus Ribavirin for 12&#xD;
      weeks.Demographic, clinical, adverse event and virological data were be collected throughout&#xD;
      treatment and post-treatment follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks</time_frame>
    <description>HCV RNA &lt;LLOQ at Week 12 after cessation of treatment</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>genotype 3a HCV</arm_group_label>
    <description>genotype 3a hepatitis C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>genotype 6 HCV</arm_group_label>
    <description>genotype 6 hepatitis C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>genotype 3b HCV</arm_group_label>
    <description>genotype 3b hepatitis C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa (sofosbuvir and velpatasvir)</intervention_name>
    <description>Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.</description>
    <arm_group_label>genotype 3a HCV</arm_group_label>
    <arm_group_label>genotype 3b HCV</arm_group_label>
    <arm_group_label>genotype 6 HCV</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The groups or cohorts will be selected from people who was diagnosed with hepatitis c at&#xD;
        the hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HCV RNA ≥ 15 IU/Ml at Screening&#xD;
&#xD;
          -  HCV genotype 3a ,3b and 6&#xD;
&#xD;
          -  Hepatitis C without decompensated cirrhosis of the liver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients failed to previous NS5A-containing DAAs therapy&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  HCC&#xD;
&#xD;
          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang Xiao hong, Professor</last_name>
    <phone>020-85253333</phone>
    <phone_ext>2372</phone_ext>
    <email>1716511502@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deparment of Infectious Diseases, the Second Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe-bin Wu, resident physician</last_name>
      <phone>13751743264</phone>
      <email>wzbice1982@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Zhe-bin Wu, resident physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Zhe-bin Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

